


Supplementary Figure S1. Age distribution of older fragile patients with metastatic colorectal cancer included in the randomized NORDIC9-study.

Biomarker	n	Progression-free Survival			Overall Survival		
		Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
CRP (mg/L)							
≤ 10	66	1.85	(1.32-2.58)	<0.001	3.36	(2.23-5.08)	<0.001
> 10	86						
dNLR							
≤ 2.2	79	1.42	(1.03-1.96)	0.034	1.89	(1.29-2.75)	0.001
> 2.2	78						
YKL-40 (μg/L)							
≤ 200	72	1.40	(0.97-2.00)	0.069	1.81	(1.20-2.74)	0.005
> 200	56						
IL-6 (ng/L)							
≤ 4.5	47	1.52	(1.04-2.21)	0.030	1.55	(0.99-2.42)	0.053
> 4.5	81						

Supplementary Table S1. Univariate cox analysis of inflammatory biomarkers CRP, dNLR, YKL-40, and IL-6 on progression-free survival and overall survival in the NORDIC9-study.

NA: Non-applicable.



Supplementary Figure S2. Kaplan-Meier survival curves demonstrating progression-free survival and overall survival stratified by treatment arm and baseline CRP levels.

Progression-free survival				Overall Survival			
Treatment arm - CRP level	Median PFS (months) 95% CI	Hazard ratio 95% CI	p-value	Treatment arm - CRP level	Median OS (months) 95% CI	Hazard ratio 95% CI	p-value
S1- CRP low	7.8 6.2-9.5	1.00	NA	S1- CRP low	25.2 15.9-NC	1.00	NA
SOx – CRP low	8.3 5.9-10.3	0.74 0.44-1.23	0.242	SOx – CRP low	21.4 18.3-27.4	1.09 0.57-2.08	0.805
S1 – CRP high	3.9 2.9-4.7	1.82 1.14-2.89	0.012	S1 – CRP high	7.8 5.8-10.4	3.85 2.15-6.90	<0.001
SOx – CRP high	4.2 3.4-6.9	1.26 0.75-2.10	0.379	SOx – CRP high	10.6 6.1-13.3	3.07 1.62-5.79	0.001

Supplementary Table S2. Progression-free survival and overall survival according to treatment arm and baseline CRP levels. Overall survival was significant shorter in patients with high CRP levels regardless treatment arm.

NA: not applicable

NC: not calculated